Related Experiment Videos

Baclofen decreases methamphetamine self-administration in rats

Robert Ranaldi1, Kerry Poeggel

  • 1Department of Psychology, Queens College, City University of New York, 65-30 Kissena Blvd., Flushing 11367, USA.

Neuroreport
|August 2, 2002
PubMed

Insights

Baclofen, a GABA-B receptor agonist, significantly reduced methamphetamine self-administration in rats. These findings suggest baclofen may be a potential treatment for methamphetamine addiction.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Addiction Research

Background:

  • Methamphetamine addiction remains a significant public health challenge.
  • GABA-B receptors play a role in modulating reward pathways.
  • Baclofen is a selective GABA-B receptor agonist with potential therapeutic applications.

Purpose of the Study:

  • To investigate the effect of baclofen on methamphetamine self-administration in a rat model.
  • To determine if baclofen can attenuate the rewarding effects of methamphetamine.

Main Methods:

  • Rats were trained to self-administer methamphetamine intravenously on a progressive ratio schedule.
  • Rats were pretreated with different doses of baclofen (2.5 or 5.0 mg/kg).
  • Methamphetamine self-administration was assessed following baclofen administration.

Main Results:

  • Baclofen significantly reduced the breakpoint for methamphetamine self-administration across all tested doses.
  • A dose-dependent rightward shift in the methamphetamine dose-response function was observed.
  • These results indicate that baclofen diminishes the reinforcing properties of methamphetamine.

Conclusions:

  • Pretreatment with baclofen effectively reduces methamphetamine reward in rats.
  • GABA-B agonists, like baclofen, show promise as a therapeutic strategy for treating drug addiction.
  • Further research into GABA-B agonists could lead to novel addiction treatments.

Related Concept Videos